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Objectives: The aims of the study were to determine the percentage of patients on regular
hemodialysis (HD) in Serbia failing to meet KDOQI guidelines targets and ﬁnd out factors
associated with the risk of time to death and the association between guidelines adherence
and patient outcome.
Methods: A cohort of 2153 patients on regular HD in 24 centers (55.7% of overall HD popula-
tion) in Serbia were followed from January 2010 to December 2012. The percentage of patients
failing to meet KDOQI guidelines targets of dialysis dose (Kt/V > 1.2), hemoglobin (>110 g/L),
serum phosphorus (1.1–1.8 mmol/L), calcium (2.1–2.4 mmol/L) and iPTH (150–300 pg/mL) was
determined. Cox proportional hazards analysis was used to select variables signiﬁcantly
associated with the risk of time to death.
Results: The patients were on regular HD for 5.3 ± 5.3 years, dialyzed 11.8 ± 1.9 h/week.
Kt/V < 1.2 had 42.4% of patients, hemoglobin <110 g/L had 66.1%, s-phosphorus <1.1 mmol/L
had 21.7% and >1.8 mmol/L 28.6%, s-calcium <2.1 mmol/L had 11.7% and >2.4 mmol/L 25.3%,
iPTH <150 pg/mL had 40% and >300 pg/mL 39.7% of patients. Using Cox model (adjust-
ment for patient age, gender, duration of HD treatment) age, duration of HD treatment,
hemoglobin, iPTH and diabetic nephropathy were selected as signiﬁcant independent pre-
dictors of time to death. When targets of ﬁve examined parameters were included in Cox
model, target for KtV, hemoglobin and iPTH were found to be signiﬁcant independent pre-
dictors of time to death.
Conclusion: Substantial proportion of patients examined failed to meet KDOQI guidelines
targets. The relative risk of time to death was associated with being outside the targets for
Kt/V, hemoglobin and iPTH.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española
de Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cumplimiento  de  las  guías  y  factores  predictivos  de  la  mortalidad  en  la
hemodiálisis.  Ensen˜anzas  de  la  experiencia  en  pacientes  de  Serbia
r  e s  u  m  e  n
Objetivos: Los objetivos del estudio fueron determinar el porcentaje de pacientes en
tratamiento de hemodiálisis (HD) regular de Serbia en los que no se alcanzaron los obje-
tivos de la guía KDOQI y determinar los factores asociados al riesgo de tiempo hasta la
muerte, así como la asociación entre el cumplimiento de la guía y los resultados clínicos.
Métodos: Se llevó a cabo un seguimiento de una cohorte de 2153 pacientes en HD regu-
lar de 24 centros de Serbia (un 55,7% de la población total en HD) entre enero de 2010 y
diciembre de 2012. Se determinó el porcentaje de pacientes que no alcanzaron los objetivos
establecidos en la guía KDOQI respecto a dosis de diálisis (Kt/V>1,2), hemoglobina (>110 g/L),
fósforo en suero (1,1-1,8 mmol/L), calcio (2,1-2,4 mmol/L) e iPTH (150-300 pg/mL). Se utilizó
un modelo de riesgos proporcionales de Cox para identiﬁcar las variables con una asociación
signiﬁcativa con el riesgo de tiempo hasta la muerte.
Resultados: Los pacientes habían estado en HD regular durante un periodo de 5,3 ± 5,3 an˜os,
con un tiempo de diálisis de 11,8 ± 1,9 horas/semana. Se observaron valores de Kt/V <1,2 en el
42,4% de los pacientes, hemoglobina <110 g/L en el 66,1%, fósforo en suero <1,1 mmol/L en
el 21,7% y >1,8 mmol/L en el 28,6%, calcio en suero <2,1 mmol/l en el 11,7% y >2,4 mmol/L
en el 25,3%, iPTH <150 pg/mL en el 40% y >300 pg/mL en el 39,7%. Con el empleo de un modelo
de Cox (con ajuste respecto a edad del paciente, sexo y duración del tratamiento de HD) se
seleccionaron las variables de edad, duración del tratamiento de HD, hemoglobina, iPTH
y nefropatía diabética como factores predictivos independientes signiﬁcativos del tiempo
hasta la muerte. Al introducir los objetivos de los cinco parámetros examinados en un mod-
elo  de Cox, se observó que los objetivos de KtV, hemoglobina e iPTH eran factores predictivos
independientes para el tiempo hasta la muerte.
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Conclusión: Una parte sustancial de los pacientes examinados no alcanzaron los objetivos
establecidos en la guía KDOQI. El riesgo relativo del tiempo hasta la muerte se asoció al
hecho de no estar en el objetivo de Kt/V, hemoglobina e iPTH.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad
Española de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In the last few decades many  guidelines for hemodialysis (HD)
based on published evidence were developed by national and
international associations.1–3 They deﬁned standards of dial-
ysis with the aim to improve results of HD treatment and
patient outcomes. The publication of these guidelines was
followed by a number of studies on the levels of guideline
adherence. Most of these studies were carried out in devel-
oped countries with similar treatment options.4–8 Data about
developing countries are insufﬁcient.
In the previous decade, conditions for HD in Serbia have
been considerably improved: new equipment for HD and
reverse osmosis has been provided, synthetic membranes are
used exclusively and agents for treatment of anemia and
mineral metabolism disorders became more  accessible. In
the recent cross section study we showed that these more
favorable dialysis treatment have brought about signiﬁcant
improvement in the treatment results.9 However, the guide-
lines adherence in our country and its comparison with those
in developed country as well as the impact of guidelines adher-
ence on patients’ outcome have not been studied.
In the present study a cohort of 2153 patients on regular HD
in Serbia were examined with the aim to determine the per-
cent of patients failing to meet KDOQI guidelines targets in ﬁve
crucial HD practice areas: dialysis dose, anemia, serum phos-
phorus, serum calcium and iPTH. The second aim was to ﬁnd
out variables signiﬁcantly associated with the risk of time to
death and to examine the association of guideline adherence
and patient outcome.
Methods
The current study analyzed data of 2153 patients on regular
HD in 24 centers in Serbia. Data were collected using a ques-
tionnaire sent to all 46 HD centers in Serbia with totally 3868
HD patients. The 24 centers responded and sent the data on
all patients aged 18 years or older who were on regular HD for
more  than 3 months on January 1st 2010. Out of 2281 patients
whose data were obtained 2153 (833 females, aged 18–90 years)
with complete data were included in the study. The study
was approved by The Ethics Committee of Zvezdara University
Medical Center and appropriate patient consent was  obtained
at all study centers.
The majority of patients were on conventional HD and 340
on hemodialﬁltration. Usually, patients were dialyzed three
times weekly for 4 h using dialyzers with polysulfone mem-
brane mainly 1.3 m2 up to 1.6 m2. In all patients the bicarbon-
ate dialysis solution was used containing 138 mmol/L sodium,
2 or 3 mmol/L potassium, 1.5–1.75 mmol/L calcium, 0.5 mmol/L
magnesium, 1 g/L glucose and bicarbonate 35 mmol/L and
dialysate ﬂow was 500 ml/min. Hemodiaﬁltration was per-
formed using a volume-controlled dialysis machine with
optional online-HDF mode (4008H, Fresenius Medical Care,
Bad Homburg, Germany).
Vascular access was arteriovenous (AV) ﬁstula in 1940
(90.1%) patients, AV graft in 65 (3.0%) of patients, tunneled cen-
tral venous catheter in 67 (3.1%) and non-tunneled catheter in
82 (3.8%) of patients.
Hemoglobin, serum levels of urea, phosphorus, calcium,
and albumin were measured by routine laboratory tests and
iPTH by chemiluminescence essay (Diagnostic Product Cor-
poration, USA). Measured calcium was corrected for level of
serum albumin with the following formula: corrected total cal-
cium (mmol/L) = TCa (mmol/L) + 0.8 [40 (g/L) − albumin (g/L)].
Dialysis dose (spKt/V) was calculated from values of blood
urea nitrogen pre- and post-dialysis, body weight, and dialy-
sis duration using the second generation Daugirdas formula.10
Patients were followed from enrollment until their death, kid-
ney transplantation, departure from the center or the end of
the study on December 31, 2012.
Data on patient demographic characteristics, medical his-
tory, HD treatment and laboratory data were obtained from
medical records at the onset of the study. Based on these
data the percentage of patients whose values failed to
meet the targets recommended by KDOQI Clinical Practice
Guidelines1 was calculated in the following areas: dialy-
sis dose (spKt/V > 1.2), anemia (hemoglobin >110 g/L), serum
phosphorus (1.1–1.8 mmol/L), serum calcium (2.1–2.4 mmol/L)
and plasma iPTH (150–300 pg/mL).
Descriptive statistics were presented as mean values and
standard deviation (SD) for the continuous variables, or
as frequencies for categorical variables. Pearson correlation
coefﬁcients were used to detect correlation among vari-
ables. Univariate Cox proportional hazards analysis was used
to select variables signiﬁcantly associated with the risk of
time to death. As independent variables patient age, gender,
primary kidney disease, type of dialysis (HD – low-ﬂux, high-
ﬂux, hemodiaﬁltration), duration of HD treatment (years), HD
hours/week, Kt/V, hemoglobin, serum calcium, phosphorus,
iPTH, systolic blood pressure, interdialytic weight gain, iron
therapy, blood transfusion, use of phosphate binders, use of
calcitriol were used. Variables: number of HD weekly, eryth-
ropoietin stimulating agents (ESA) dose/week, duration of
Epo treatment (years), product of calcium and phosphorus
were not included in analysis due to colinearity. Signiﬁcant
variables in univariate analysis (p < 0.10) were tested in a mul-
tivariate Cox models using the backward stepwise method.
The p values of less than 0.05 were considered as statistically
signiﬁcant. Models were adjusted for patient age, gender and
duration of HD treatment (years).
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All analyses were performed using the SPSS statistical soft-
ware package (Version 10; SPSS). IBM Corp. Released 2012. IBM
SPSS Statistics for Windows, Version 21.0. Armonk, NY:
IBM Corp.
Results
The study involved 2153 patients with mean age of 59 years,
but 436 (20.3%) patients were older than 70 years. Character-
istics of patients and HD treatment at the onset of the study
are presented in Table 1. Patients were on regular HD treat-
ment for averagely 5.3 years and the most frequent cause
of end-stage renal disease was hypertension. Dialyzers with
polysulfone membranes were used in all patients: low-ﬂux
dialyzers in 29.8%, high-ﬂux dialyzers in 54.4% and 15.7% of
patients were on hemodiaﬁltration. Mean HD duration per
week was 11.8 h and majority of patients had 12 and more
hours dialysis weekly (84.5%), but 213 (9.9%) of patients had
less than 9 h of HD weekly.
Table 2 shows that 65.1% of patients were treated with ESA,
most of them with epoetin and 378 (17.6%) with darbepoetin
alpha. Intravenous iron was used in 34.7% of patients and
13.7% patients received blood transfusions when it was neces-
sary. At the onset of the study mean (SD) hemoglobin level was
102 (17) g/L, serum ferritin level 591.4 (557.5) ng/mL and trans-
ferrin saturation 30.2 (16.1)%. Phosphate binders were used by
95% of patients and it was mainly calcium carbonate in the
mean daily dose of 3.15 g ± 1.59 g.
Results presented in Table 3 show that mean values of
Kt/V, serum phosphorus and calcium levels and calcium-
phosphorus product were in guidelines target ranges. On the
other hand, substantial percentage of patients was outside
guidelines targets and this percentage was the lowest for
calcium-phosphorus product and the highest for serum iPTH
level. Fig. 1 shows that among patients with individual values
outside guidelines targets there were 14.4% of patients with
Kt/V below 1.0, 41.4% patients with hemoglobin below 100 g/L,
13.6% of patients with serum calcium above 2.6 mmol/L and
21.5% of patients with iPTH above 600 pg/mL.
During the three-year follow-up period, 577 (26.7%) patients
died, 44 (2%) were transplanted, 69 (3.2%) were lost from the
follow-up and 1463 remained on regular HD. When parameters
listed in methods were analyzed by univariate Cox propor-
tional hazard model, the following variables were selected as
signiﬁcant predictors of time to death: age, gender, duration of
HD treatment, underlying kidney disease (diabetic nephropa-
thy, Balkan nephropathy, polycystic kidney disease), hours of
Table 1 – Characteristics of patients and hemodialysis
treatment at the onset of the study.
Number 2153
Gender
Males 1320 (61.3%)
Females 833 (38.7%)
Age, years
Range 18–90
Mean ± SD 59.0 ± 12.5
>70 years 436 (20.3%)
Diagnosis
Glomerulonephritis 370 (18.4)
TIN (without Balkan nephropathy) 117 (5.8)
Balkan nephropathy 90 (4.5)
Hypertensive nephropathy 540 (26.8)
Diabetic nephropathy 276 (13.7)
Polycystic kidney disease 168 (8.4)
Other 253 (12.6)
Unknown 195 (9.7)
Blood pressure, mmHg
Systolic 136 ± 21
Diastolic 77 ± 10
Vintage, years
Range 0.5–35
Mean ± SD 5.3 ± 5.3
Dialysis treatment
Low-ﬂux dialyzers 642 (29.8%)
High-ﬂux dialyzers 1171 (54.4%)
Hemodiaﬁltration 340 (15.8%)
Dialysis hours/week 2.9 ± 0.3
Dialysis time 11.8  ± 1.9
<9 h/week 213 (9.9%)
9–12 h/week 119 (5.5%)
12 h/week 1585 (73.6%)
>12 h/week 236 (10.9%)
ID weight gain, kg
Range 0–9
Mean ± SD 2.8 ± 1.1
ID – interdialytic.
Mean values (SD) are presented for continuous variables.
HD/week, Kt/V, hemoglobin, s-phosphorus, s-calcium, iPTH,
use of oral iron and number of transfusions per year. Com-
bining these variables in multivariate Cox proportional hazard
model with adjustment for patient age, gender and duration of
HD treatment, the signiﬁcant independent predictors of time
to death were selected (Table 4).
Table 2 – Treatment of anemia and mineral metabolism disorders.
Iron, number (%) of treated patients Phosphate binders, number (%)of treated patients
Oral 247 (11.5%) CaCO3 1602 (74.4%)
i.v. 747 (34.7%) Other 108 (20.6%)
ESA use, number (%) 1402a (65.1%) Not treated 443 (5.0%)
ESA dosage, U/week (mean ± SD)a 3574 ± 2601 Vitamin D3, number (%)of treated patients
Transfusion One-alphaD3 603 (28.0%)
Number of patients receiving 296 (13.7%) 1,25 D3 349 (16.2%)
Units/year 0.72 ± 2.44 Not treated 1201 (55.8%)
a 378 (17.6%) of patients were treated with darbepoetin alpha and the others used epoetin.
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Table 3 – Mean values (±SD) and ranges of variables
examined and proportion of patients outside guidelines
targets at the onset of the study.
Single pool Kt/V
Range 0.64–2.84
Mean ± SD 1.24 ± 0.31
<1.2, no. (%) of patients 912 (42.4)
Hemoglobin, g/l
Range 55–142
Mean ± SD 102 ± 17
<110 g/L, no. (%) of patients 1423 (66.1)
S-phosphorus, mmol/L
Range 0.42–4.9
Mean ± SD 1.58 ± 0.56
<1.1 mmol/L, no. (%) of patients 467 (21.7)
>1.8 mmol/L, no. (%) of patients 616 (28.6)
s-clacium, mmol/L
Range 0.90–3.58
Mean ± SD 2.31 ± 0.29
<2.1 mmol/L, no. (%) of patients 252 (11.7)
>2.4 mmol/L, no. (%) of patients 545 (25.3)
s-calcium × phsophorus, mmol2/L2
Range 0.91–13.9
Mean ± SD 3.74 ± 1.39
>4.4 mmol2/L2, no. (%) of patients 626 (29.1)
s-iPTH, pg/mL
Range 1.2–4480.0
Mean ± SD 407.8 ± 512.4
<150 pg/mL, no. (%) of patients 861 (40.0)
>300 pg/mL, no. (%) of patients 855 (39.7)
We also used a Cox proportional hazards model to inves-
tigate the association between mortality and satisfying the
guidelines targets. When targets of Kt/V, hemoglobin, serum
phosphorus, calcium and iPTH were included in multivari-
ate Cox model with adjustment for patient age, gender and
duration of HD treatment (years), target values for Kt/V,
hemoglobin and iPTH were found to be the signiﬁcant inde-
pendent predictors of time to death (Table 5). When Cox model
was  adjusted for patient age, gender, duration of HD treatment
(years) and diabetic nephropathy the same targets values were
selected as signiﬁcant independent predictors of time to death
as well as diabetic nephropathy. The values of regression coef-
ﬁcient (B), relative risk (RR) and conﬁdence interval of relative
risk (CI) as well as signiﬁcance of coefﬁcient (p) were as follows:
Kt/V [B = −0.18, RR(CI) = 0.83 (0.68–1.01), p = 0.042], hemoglobin
[B = −0.22, RR(CI) = 0.80 (0.66–0.96), p = 0.012], iPTH [B = −0.35,
RR(CI) = 0.71 (0.51–0.98), p = 0.042] and diabetic nephropathy
[B = 0.68, RR(CI) = 1.98 (1.52–2.55), p < 0.0001].
Discussion
The study involved 2153 patients on regular HD for aver-
agely 5.3 years, dialyzed averagely 11.8 h weekly on dialyzers
with polysulfone membranes (15.7% on hemodiaﬁltration).
The study was carried out in order to determine the percentage
of patients not reaching the KDOQI guidelines targets in the
ﬁve areas of HD practice and to ﬁnd out whether the compli-
ance with these targets was associated with patient outcome.
Percentage of patients outside KDOQI guidelines targets was
42.4% for Kt/V, 66.1% for hemoglobin, 50.3% for serum phos-
phorus, 37% for serum calcium and 79.7%, for serum iPTH
levels. Cox proportional hazard model with adjustment for
patient age, gender and duration of HD  treatment (years)
found age, duration of HD treatment, hemoglobin, iPTH and
diabetic nephropathy as signiﬁcant independent predictors of
time to death. When targets of Kt/V, hemoglobin, serum phos-
phorus, calcium and iPTH were included in multivariate Cox
model, target values for Kt/V, hemoglobin and iPTH were found
to be the signiﬁcant predictors of time to death.
During the last few decades, several guidelines have been
developed recommending standards for health care of HD
patients.1–3 Soon thereafter, it was obvious that guideline
adherence is a very difﬁcult task to manage. Numerous
national and international studies were undertaken to ﬁnd
out the proportion of patients failing to meet guidelines tar-
gets as well as the association of guidelines compliance and
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Table 4 – Relative risk of mortality: multivariate Cox proportional hazard model.
Variable B  RR (CI) p
Male gender −0.139 0.87 (0.66−1.15) 0.326
Age, years 0.054 1.06 (1.04−1.07) <0.0001
Duration of HD treatment, years −0.660 0.52 (0.47−0.57) <0.0001
Hours of HD/week −0.100 0.91 (0.82−1.01) 0.062
Hemoglobin, g/L −0.010 0.99 (0.98−1.00) 0.019
iPTH, pg/mL 0.001 1.00 (1.00−1.01) <0.0001
Diabetic nephropathy, yes 0.672 1.96 (1.39−2.76) <0.0001
RR – relative risk, Exp(B), CI – 95% conﬁdence interval of Exp(B), p – signiﬁcance of coefﬁcient.
patients’ outcome.4,6,7,11 Most of these studies were carried
out in developed countries. In recent years, the number of
papers presenting epidemiological data on RRT in developing
countries increased, but papers on the results of HD treat-
ment and compliance with guidelines in developing countries
are scarce.12–14 Recently, DOPPS 5 including several developing
countries was initiated and their ﬁrst results were reported
at this years’s ERA-EDTA Congress.15–17 Serbia is one of the
developing countries that overpassed heavy nineties and that
now has satisfactory conditions for HD treatment. In addition,
at numerous scientiﬁc and educative meetings of our soci-
ety recommendation of guidelines and their updating were
discussed. This prompted us to check guidelines adherence
and HD patient outcome in our country and compare it with
those in other developing as well as developed countries. We
selected KDOQI guidelines for comparative analysis since they
were traditionally used by the most of the HD centers until
2012 when KDIGO guidelines started to be adopted as a daily
practice.
In examined cohort of HD patients mean Kt/V was
1.24 ± 0.31 and 42.4% of patients had Kt/V below 1.2, the mini-
mum adequate dose proposed by KDOQI guidelines. However,
14.4% of patients had Kt/V below 1.0. Results of DOPPS I and II
showed great variation in percentage of patients with spKt/V
below 1.25. Nevertheless, in all countries that participated
in the study percent of patients with spKt/V  below 1.2 was
lower in DOPPS II (ranging between 10% and 31%) than in
DOPPS I (14–42%). In our country percent of patients failing
to meet Kt/V target decreased signiﬁcantly during the last
decade,9 but it is still higher than those reported in DOPPS
II, although DOPPS II was ﬁnished six years before our study.
Mean Kt/V for HD population presented here was comparable
to those reported in several observation national studies
from developed countries,6,18 but higher than in some devel-
oping countries.13,14 However, mean Kt/V reported recently
for HD patients from Russia and Turkey, two developing
countries included in DOPPS 5, was 1.49 ± 0.33 and 1.60 ± 0.31,
respectively.15,16
Our study showed that Kt/V was a signiﬁcant predictor of
mortality that was reported previously and was the impetus
for improvement of HD adequacy. Numerous studies indi-
cated beneﬁcial effect of increasing dialysis dose on patient
survival,19–21 although it is still not proven that increasing
the Kt/V above the guidelines target would reduce patient
mortality.22,23 DOPPS study showed that not only dialysis dose
but blood ﬂow rate, duration of HD and type of dialysis had
signiﬁcant inﬂuence on patient survival.24,25 Nevertheless, for
nephrologists in our country increasing of the HD adequacy
and decreasing the percentage of patients failing to meet Kt/V
target remains and important task. To achieve this it will be
necessary to ﬁrst carefully analyze the factors responsible
for such high percentage of patients with Kt/V below recom-
mended minimum of Kt/V. However, these factors were not
objective of the present study. From the deﬁnition of Kt/V it
is clear that it depends on dialyzer characteristics and dialy-
sis time but increasing Kt/V depends primarily on the rate of
blood ﬂow through the dialyzer and a good vascular access
is a key factor for achieving good blood ﬂow and Kt/V. The
vast majority of our patients had AV ﬁstula but the data on
blood ﬂow as well as on many  other factors inﬂuencing blood
ﬂow and Kt/V (comorbidities, hemodynamic stability during
RRT, serum albumin, hematocrit, patient adherence to the
prescribed regimen) were not available in the present study.
The analysis of the factors inﬂuencing low Kt/V in 42.4% of
Table 5 – Relative risk of mortality: multivariate Cox proportional hazard model included guidelines target values as
independent variables.
Variable B RR (CI) p
Male gender −0.25 0.78 (0.63–0.95) 0.017
Age, years 0.04 1.04 (1.03–1.05) <0.0001
Duration of HD treatment, years −0.59 0.55 (0.51–0.59) <0.0001
Hours of HD/week −0.04 0.96 (0.91–1.02) 0.216
Kt/V >1.2 −0.21 0.81 (0.66–0.98) 0.037
Hemoglobin >110 g/L −0.70 0.51 (0.36–0.73) <0.0001
s-phosphorus 1.1–1.8 mmol/L −0.07 0.93 (0.77–1.12) 0.442
s-calcium 2.1–2.4 mmol/L −0.06  0.94 (0.78–1.13) 0.531
iPTH 150–300, pg/ml −0.35 0.71 (0.50–0.99) 0.045
RR – relative risk, Exp(B), CI – 95% conﬁdence interval of Exp(B), p – signiﬁcance of coefﬁcient.
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our patients requires additional detailed study. Using avail-
able data from this study, we found signiﬁcant correlation
(p < 0.0001) between Kt/V and age, body weight, hours of dial-
ysis weekly, type of dialysis (low and high-ﬂux dialyzers,
hemodialﬁltration).
After 2004, ESA has become more  accessible in our HD
units and hemoglobin levels increased signiﬁcantly.9 How-
ever, at the onset of the present study 66.1% of patients had
hemoglobin level below KDOQI guideline target of 110 g/L
and this percentage is lower than in most of developed
countries26–28 but similar or even higher than in develop-
ing countries.29–31 Mean hemoglobin level was lower in HD
patients examined here than in those treated in all countries
participating in DOPPS I–III except in Japan.32 In Japan maxi-
mal  ESA dose was limited by public reimbursement, but mean
ESA dose in this country was about 50% higher than the
mean dose used in our HD patients. Our Health Insurance
Fund determined hemoglobin between 100 and 110 g/L as tar-
get hemoglobin. However, 41.4% of patients had hemoglobin
below this target that is much more  than the percentage
shown in our previous cross sectional study.9 That could be
explained not only by the limitation of our Health Insur-
ance Fund but also by occasional ESA shortages caused by
irregular supply due to prolonged tender procedures. It shows
that compliance with guidelines depends not only on their
knowledge but also of local circumstances. The importance
of achieving target hemoglobin levels derived from its signif-
icant association with mortality showed in the present study
as well as in many  others.5,33–35 Therefore, the continuous
effort to increase the percentage of patients achieving target
hemoglobin value remains an important task.
Percentage of patients who fell within K/DOQI recom-
mended range for serum phosphorus (49.7%) and iPTH (20.3%)
was comparable with those in the DOPPS studies.5,36 It is
obvious that in our HD population like in many  others7,30,36
patients with low iPTH level represent twice the bigger prob-
lem than those with severe hyperparathyroidism while the
opposite is found in some other countries.31,37 Percentage of
patients who  achieved targets for serum calcium was higher
(63%) than in DOPPS studies and similar to results presented
in some recent studies.7,38
Numerous studies found a signiﬁcant relationship between
serum levels of phosphorus, calcium, PTH and mortality.39–41
However, several meta-analyses reported conﬂicting data:
some found signiﬁcant association between increased val-
ues of all three parameters and mortality,42 others found
association only between high phosphorus serum level and
mortality,43 while some found different relationship between
mortality and these three parameters depending on whether
their values were above or below recommended targets.44,45
Using univariate Cox proportional hazard model we found
higher mortality risk in patients with higher phosphorus
and iPTH and lower calcium serum levels. However, only
iPTH appeared as a signiﬁcant independent predictor of time
to death in multivariate Cox proportional hazard model.
Although majority of our patients had lower iPTH than that
proposed by guideline, those with higher iPTH value are at
higher risk of mortality. In addition, when targets of all ﬁve
examined HD practice parameters were involved in Cox pro-
portional hazard model, being outside target range for iPTH
was also found to be associated with signiﬁcantly higher risk
for death.
This study has several limitations. Clinical and laboratory
parameters measured only in the onset of the study were
included in the analysis, although multiple measurements of
these parameters would be more  conclusive since interven-
tions by nephrologist were guided by initial results.
The limitation of this study is that the data on comor-
bid conditions were not available and adjusting for these
conditions in the Cox models was not possible. Comorbid-
ity was found as a strong predictor of mortality in incident
HD patients.46,47 However, the study performed in incident
patients registered in European Renal Association–European
Dialysis and Transplant Association Registry showed that
after adjustment for age, gender, primary renal disease and
treatment modality the inﬂuence of comorbidity was less
important than expected.48 Analysis of results obtained in
DOPPS study also showed that adjustment for patient demo-
graphics and comorbidities only partially reduced survival
differences by location and other factors that might contribute
to differing outcomes were described.49 Although these data
suggest that our results would insigniﬁcantly change if comor-
bidity was accounted for, the impact of comorbidity required
to be examined. The present study was aimed to ﬁnd out com-
pliance with KDOQI guidelines targets and it has been shown
that substantial proportion of patients examined failed to
meet these targets. Moreover, the noncompliance with guide-
lines targets was associated with an increased risk of death.
This study as a starting point would be signiﬁcant only if the
research continues to ﬁnd out all potential factors associated
with the failure to achieve guidelines targets which is beyond
the scope of this paper.
Conclusion
According to the present analysis critical points of HD practice
in Serbia included low dialysis dose (in 42.4% of patients), low
hemoglobin level (in 66.1%), hyperphosphatemia (in 28.6%)
and low (in 40%) and high (in 21.5%) iPTH levels. Age, duration
of HD treatment, hemoglobin, iPTH and diabetic nephropathy
were selected as signiﬁcant independent predictors of time to
death. The relative risk of time to death was associated with
being outside the guidelines targets for Kt/V, hemoglobin and
iPTH. The study suggests vast opportunities for the improve-
ment of HD patient care and possibly patient outcome.
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